A stock with a 6-month gain of over 1500% is normally certain to raise some eyebrows. But, “normally” is a long distance away from the current reality, and that figure is the upside posted by shares of molecular diagnostics player Co-Diagnostics (CODX) since the turn of the year.While certainly not common place, these massive gains are not completely out of the ordinary in 2020, although primarily reserved for one specific group of stocks: those in the hunt for coronavirus related solutions.And CODX belongs squarely in that group. Actually, that’s not quite on point – Co-Diagnostics already has a solution, in …read more
Source:: Yahoo Finance
